Neurology Minute
American Academy of Neurology
0
The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.
Episodes
-
Parkinsonism Identified as Potential Side Effect of Immune Checkpoint Inhibitors 18.11.2026 2mDr. Halley Alexander discusses the Neurology Today article, "Parkinsonism Identified as Potential Side Effect of Immune Checkpoint Inhibitors" by Stacey Burling, available in the November 5th issue of Neurology Today or at neurologytoday.com. Help shape the future of the Neurology Minute® Daily Briefing. Take our listener survey today! Show citation: Birzu C, Bihan K, et al. Parkinsonism as a Potential Neurologic Immune-Mediated Adverse Event of Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2026 Sep;13(5):e200644. doi: 10.1212/NXI.0000000000200644 -
Establishing Potosi Virus as a Human Pathogen - Part 4 17.11.2026 2mIn the final episode of this series, Dr. Stacey Clardy and Dr. Justin Abbatemarco discuss considerations for timing vaccinations in patients who are preparing to start or are already receiving anti-CD20 therapy. Help shape the future of the Neurology Minute® Daily Briefing. Take our listener survey today! Show citation: Abbatemarco JR, Begum F, Villalba JA, et al. Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Neurology. 2026;107(10):e218683. doi:10.1212/WNL.0000000000218683 -
November 2026 President Spotlight: The Future of Neurology Therapies 16.11.2026 3mIn the November episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost explore how new therapies, diagnostic tools, and emerging technologies are shaping the future of neurology. Stay informed by watching the President's Spotlight video. Help shape the future of the Neurology Minute® Daily Briefing. Take our listener survey today! -
Establishing Potosi Virus as a Human Pathogen - Part 3 13.11.2026 2mIn part three of this series, Dr. Stacey Clardy and Dr. Justin Abbatemarco discuss practical advice for people receiving anti-CD20 therapy to reduce their exposure to mosquitoes and ticks. Show citation: Abbatemarco JR, Begum F, Villalba JA, et al. Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Neurology. 2026;107(10):e218683. doi:10.1212/WNL.0000000000218683 -
Establishing Potosi Virus as a Human Pathogen - Part 2 12.11.2026 3mIn part two of this series, Dr. Stacey Clardy and Dr. Justin Abbatemarco discuss the household exposures clinicians should consider when a patient receiving B-cell therapy develops fever, confusion, or new difficulty walking. Show citation: Abbatemarco JR, Begum F, Villalba JA, et al. Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient. Neurology. 2026;107(10):e218683. doi:10.1212/WNL.0000000000218683 -
Establishing Potosi Virus as a Human Pathogen - Part 1 11.11.2026 2mIn part one of this series, Dr. Stacey Clardy and Dr. Justin Abbatemarco discuss why a nearly normal spinal fluid profile or a negative antibody test can be misleading when evaluating a patient receiving anti-CD20 therapy for possible encephalitis or another viral infection. -
Facial Pain Series - Part 2 10.11.2026 4mIn the second episode of this series, Dr. Derek Stitt discusses Glossopharyngeal neuralgia and nervus intermedius neuralgia, two types of cranial neuralgia. -
Facial Pain Series - Part 1 09.11.2026 3mIn part one of this series, Dr. Derek Stitt discusses trigeminal neuralgia and, more specifically, how to make sure that's actually the diagnosis. -
October 26, 2026 Capitol Hill Report: Conrad 30 06.11.2026 2mIn this episode, Dr. Jose Posas reviews the Capitol Hill Report from October 26th, discussing international medical graduates, the Conrad 30 program, and the AAN's efforts to strengthen visa pathways for physicians serving communities across the US. Stay updated with what's happening on the hill by visiting aan.com/chr. Learn how you can get involved with AAN advocacy. -
Youth Football and the Epidemic of Pediatric Brain Injury - Part 2 05.11.2026 2mIn part two of this series, Dr. Dara Albert and Isaac Thorman discuss guidance for parents weighing whether to let their children play tackle football. Show citation: Thorman IB, Feldstein E, Sacknovitz A, et al. Youth Football and the Epidemic of Pediatric Brain Injury: Neurologic and Psychiatric Outcomes in a Cohort of 72,025 Concussions. Neurol Clin Pract. 2026;16(6):e200656. doi:10.1212/CPJ.0000000000200656 -
Youth Football and the Epidemic of Pediatric Brain Injury - Part 1 04.11.2026 1mIn part one of this series, Dr. Dara Albert and Isaac Thorman discuss football as a major contributor to pediatric traumatic brain injury and its association with subsequent head injuries. Show citation: Thorman IB, Feldstein E, Sacknovitz A, et al. Youth Football and the Epidemic of Pediatric Brain Injury: Neurologic and Psychiatric Outcomes in a Cohort of 72,025 Concussions. Neurol Clin Pract. 2026;16(6):e200656. doi:10.1212/CPJ.0000000000200656 -
Acute Optic Neuropathy in Older Adults 03.11.2026 3mDr. Justin Abbatemarco discusses an article that helps us distinguish between the causes of acute optic neuropathy. Show citation: Tisavipat N, Stiebel-Kalish H, Palevski D, et al. Acute Optic Neuropathy in Older Adults: Differentiating Between MOGAD Optic Neuritis and Nonarteritic Anterior Ischemic Optic Neuropathy. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200214. doi:10.1212/NXI.0000000000200214 -
Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis 02.11.2026 3mDr. Aaron Zelikovich discusses how gefurulimab may offer an effective and convenient treatment option for adults with generalized myasthenia gravis. Show citation: Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83(9):841-850. doi:10.1001/jamaneurol.2026.2333 -
Trends in Emergent Interfacility Ischemic Stroke Transfers 30.10.2026 2mDr. Andy Southerland and Dr. Matthew Gusler discuss how emergent interfacility transfers for ischemic stroke have changed and the factors associated with which patients are transferred. Show citation: Gusler MT, Deligkaris C, Zha AM, Burke JF. Trends in Emergent Interfacility Ischemic Stroke Transfers, 2016-2022. Neurology. 2026;107(7):e218499. doi:10.1212/WNL.0000000000218499 -
Clinical Reasoning: Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia in a Patient With MS 29.10.2026 3mDr. Zohaib Siddiqi and Dr. Michel Toledano discuss the diagnosis and management of infectious rhombencephalitis in patients receiving immunomodulatory therapy. Show citation: Trentadue T, Martinez Sosa S, Itoh CY, et al. Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia. Neurology. 2025;105(12):e214429. doi:10.1212/WNL.0000000000214429 -
Optimizing Management of Episodic Cluster Headache 28.10.2026 2mDr. Tesha Monteith shares practical tips for improving outcomes for patients with episodic cluster headache. -
Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Adults with Migraine 27.10.2026 2mDr. Tesha Monteith discusses growing evidence supporting CGRP-targeted therapies as first-line preventive treatment options for people with migraine. Show citation: Reuter U, Dycke AV, Versijpt J, et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Lancet Neurol. 2026;25(9):806-817. doi:10.1016/S1474-4422(26)00214-0 -
Rethinking Seronegative NMOSD 26.10.2026 2mDr. Casey Kozak discusses why most patients referred with seronegative NMOSD ultimately receive alternative diagnoses, underscoring the challenges of accurate diagnosis in antibody-negative cases. Show citation: Lang MV, Welk GM, Tajfirouz DA, et al. Unveiling Misdiagnosis: Rethinking Seronegative NMOSD. Mult Scler. 2025;31(11):1381-1384. doi:10.1177/13524585251360648 -
The Menopause Transition and Epilepsy 22.10.2026 1mDr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife. Show citation: Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650 -
The Menopause Transition and Epilepsy 22.10.2026 1mDr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife. Show citation: Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650
Popular in
The podcast also appears in the podcast charts of these countries.